8-K filed Aug 6, 2026 at 07:52 ET
Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL product revenue and $28.1M in non-cash royalty revenue. The company highlighted its oversubscribed $85M private placement to fund the Phase 3 ROBBIN trial, but also disclosed the termination of the BATTMAN Phase 3 study due to funding prioritization. The filing is neutral as the revenue beat is largely non-cash royalty revenue, and the strategic pivot to ROBBIN comes at the cost of the BATTMAN trial, creating offsetting signals for a pre-revenue biotech.